Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

4O55

HIV-1 Integrase Catalytic Core Domain Complexed with Allosteric Inhibitor (2S)-tert-butoxy[6-(5-chloro-1H-benzimidazol-2-yl)-2,5-dimethyl-4-phenylpyridin-3-yl]ethanoic acid

Summary for 4O55
Entry DOI10.2210/pdb4o55/pdb
Related1ITG 4O0J 4O5B
DescriptorIntegrase, (2S)-tert-butoxy[6-(5-chloro-1H-benzimidazol-2-yl)-2,5-dimethyl-4-phenylpyridin-3-yl]ethanoic acid, SULFATE ION, ... (4 entities in total)
Functional Keywordshiv integrase, ccd, dde motif, allosteric inhibitor, viral protein-inhibitor complex, viral protein/inhibitor
Biological sourceHuman immunodeficiency virus type 1 (HIV-1)
Cellular locationGag-Pol polyprotein: Host cell membrane; Lipid-anchor . Matrix protein p17: Virion membrane; Lipid- anchor . Capsid protein p24: Virion . Nucleocapsid protein p7: Virion . Reverse transcriptase/ribonuclease H: Virion . Integrase: Virion : P12497
Total number of polymer chains1
Total formula weight18904.59
Authors
Feng, L.,Kvaratskhelia, M. (deposition date: 2013-12-19, release date: 2014-07-02, Last modification date: 2017-11-22)
Primary citationSharma, A.,Slaughter, A.,Jena, N.,Feng, L.,Kessl, J.J.,Fadel, H.J.,Malani, N.,Male, F.,Wu, L.,Poeschla, E.,Bushman, F.D.,Fuchs, J.R.,Kvaratskhelia, M.
A New Class of Multimerization Selective Inhibitors of HIV-1 Integrase.
Plos Pathog., 10:e1004171-e1004171, 2014
Cited by
PubMed Abstract: The quinoline-based allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are promising candidates for clinically useful antiviral agents. Studies using these compounds have highlighted the role of IN in both early and late stages of virus replication. However, dissecting the exact mechanism of action of the quinoline-based ALLINIs has been complicated by the multifunctional nature of these inhibitors because they both inhibit IN binding with its cofactor LEDGF/p75 and promote aberrant IN multimerization with similar potencies in vitro. Here we report design of small molecules that allowed us to probe the role of HIV-1 IN multimerization independently from IN-LEDGF/p75 interactions in infected cells. We altered the rigid quinoline moiety in ALLINIs and designed pyridine-based molecules with a rotatable single bond to allow these compounds to bridge between interacting IN subunits optimally and promote oligomerization. The most potent pyridine-based inhibitor, KF116, potently (EC50 of 0.024 µM) blocked HIV-1 replication by inducing aberrant IN multimerization in virus particles, whereas it was not effective when added to target cells. Furthermore, KF116 inhibited the HIV-1 IN variant with the A128T substitution, which confers resistance to the majority of quinoline-based ALLINIs. A genome-wide HIV-1 integration site analysis demonstrated that addition of KF116 to target or producer cells did not affect LEDGF/p75-dependent HIV-1 integration in host chromosomes, indicating that this compound is not detectably inhibiting IN-LEDGF/p75 binding. These findings delineate the significance of correctly ordered IN structure for HIV-1 particle morphogenesis and demonstrate feasibility of exploiting IN multimerization as a therapeutic target. Furthermore, pyridine-based compounds present a novel class of multimerization selective IN inhibitors as investigational probes for HIV-1 molecular biology.
PubMed: 24874515
DOI: 10.1371/journal.ppat.1004171
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.24 Å)
Structure validation

227111

PDB entries from 2024-11-06

PDB statisticsPDBj update infoContact PDBjnumon